Curated Wealth Partners’s AbbVie ABBV Stock Holding History

Curated Wealth Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,561	Closed	-$466K	–	134
2024 Q1	$466K	Buy	+2,561	New	+$441K	0.07%	90

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Curated Wealth Partners's ABBV Position: Q2 2026 in Review

Curated Wealth Partners increased its AbbVie (ABBV) stake by 49% in Q2 2026, buying an estimated $222K and bringing the position to 3,149 shares worth $792K. The position accounts for 0.09% of the portfolio, ranked #78.

Curated Wealth Partners first reported a position in ABBV in Q1 2021 and has held it in 21 quarters since. 4,219 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Curated Wealth Partners held 3,149 shares of AbbVie worth $792K as of Q2 2026.
Curated Wealth Partners bought 1,032 AbbVie shares in Q2 2026, an estimated $222K.
AbbVie made up 0.09% of Curated Wealth Partners's portfolio in Q2 2026, its #78 holding.
Curated Wealth Partners first reported a position in AbbVie in Q1 2021 and has held it in 21 quarters since.
4,219 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Curated Wealth Partners's 13F filing for Q2 2026, filed 13 Jul 2026.